I do not own this stock of Johnson and Johnson (NYSE-JNJ), but I used to. As Canadians, we are informed we ought to be buying US shares for our collection. It is often recommended that we have at least 25% of our stock portfolio in US shares. I have implemented this never, although I have tried dipping into the US market, but I have never there made hardly any money. I bought a few of this stock in June 2005 and realized a year later, in June of 2006 that it was going nowhere for me personally and sold.
I lost almost 17% of my investment. When I bought in 2005, all the analysts were saying that it was a good buy at that right time. Since this is a US dividend growth stock, dividends payments will vary with the exchange rate therefore as a Canadian you won’t ever know precisely what dividends you will receive.
At different schedules this will be different. The dividends are moderate, as are the dividend increases. For the 5-calendar year intervals ending in December 2014 and 2015, the total come back has been good for Canadian traders in the stock with a total return at 15.4% and 21.5% per yr. For Canadians in the 5-year periods ending in December 2001 and 2002 Total Return was also proficient at 24.83% and 14.26%, respectively.
However, the 5 12 months periods closing in December 2003 to 2011 the total return per 12 months were negative or very low. Year period That is 9. In the event that you had held this stock for 5, year periods and paid a median price 10 or 15, you’d be earning a dividend yield 5.02%, 5%, or 6.2% per yr on your original investment. This stock has very good personal debt ratios.
Growth over the past 5 and a decade have been low to moderate. The Revenue per Share growth within the last 5 and 10 years reaches 2.5% and 4.6% per 12 months. The EPS growth within the last 5 and 10 years is at 2.8% and 4.7% per 12 months. The development within the last 5 and a decade are at 0.7% and 4.7% per 12 months. This is lower development than the stock price growth with capital benefits at 10.7% and 5.5% per season over the past 5 and 10 years.
5.98. This stock price testing suggests that the stock price is realistic but above the median. It is getting close to expensive. 114.91. This stock price tests suggest that the stock price is relatively expensive. 12 months median Price/Publication Value per Talk about Ratio of 3 I get a 10.71. The existing P/B Ratio is 4.35 values some 17% higher. 26.41. This stock price screening shows that the stock price is affordable but above the median. It is getting near to expensive. 114.91. The historical median Dividend yield is 2.18% a value some 27.7% lower.
- ► Aug 03 (1)
- 19, Moskovska Str
- 4 years ago from Connecticut
- Hedge Fund Prime Brokers
This suggests that the stock price is cheap on a historical basis. The 10-season median dividend yield is higher at 3.06%, a value some 9% greater than today dividend yield. On the 10 12 months basis, today stock is affordable relatively, but above the median. When I look at experts’ suggestions, I find Strong Buy, Buy, and Hold recommendations. A couple of more Holds than Buys however the consensus is a Buy.
12.90% with 10.11% from capital increases and 2.78% from dividends. This associated press release in the Toronto Star talks about some women winning suit against Johnson and Johnson over the utilization of talcum power. There are different opinions about the use of talcum powder and sadly being in healthcare industry can include being appropriate.
